Senior Director, Clinical Development
Immunome, Inc.Highlight
Summary
About the Role
About You
- M.D., D.O. or equivalent with board certification in medical oncology or hematology preferred.
- A minimum of 2-4+ years of experience leading Clinical Development and Phase 1 – 3 oncology clinical trials in a biotech or pharmaceutical setting.
- Proven experience advancing therapeutic programs from IND-enabling studies through early and late-stage clinical development.
- Understanding of FDA and EMA regulatory requirements and a successful track record in regulatory interactions.
- Demonstrated leadership and ability to effectively manage cross-functional teams.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.